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Abstract
Background: Aetiologically, genetic and environmental factors having an uneven spatial distribution may underlie
Parkinson's disease (PD). Undiagnosis of PD in selected regions might have limited access to treatment with levodopa
and simultaneously, if present at death, determined PD underreporting at the death record. The purpose of this study
was to describe and analyse municipal mortality due to PD in Spain in aetiological and interventional perspective.
Methods: PD mortality at a municipal level was modelled using the Besag-York- Molliè autoregressive spatial model,
combining demographic information with cause-of-death diagnostic data (International Classification of Diseases 9th
Revision (ICD-9) code 332.0). Municipal relative risks (RRs) were independently estimated for women, men and both
sexes, and plotted on maps depicting smoothed RR estimates and the distribution of the posterior probability of RR>1.
Results: A south-north gradient, with large geographical areas suggesting clustered towns with high mortality, was seen
in Asturias, the Basque Country, Balearic Islands and, particularly, in the Lower Ebro valley around Tarragona. Similarly,
there was a suggestion that lowest mortality was clustered in the south-east and south-west. We identified some isolated
or clustered municipalities with high mortality that were situated near industrial plants reported to be associated with
environmental xenobiotic emissions. However, the same pattern was also observed for some cities with low mortality.
Conclusion: Municipal PD mortality in Spain was unevenly distributed. Patterns were roughly similar to reported
provincial PD mortality and use of levodopa. While the overall pattern appears to result from spatially selective PD
undiagnosis, and can not be ascribed to industrial emissions, it can not be excluded that selected "hot spots" reflect
genetic factors and/or environmental exposures inducing parkinsonism. A few municipal populations, located in low-
mortality-risk areas in the vicinity of polluting plants or registering high excess PD mortality, might constitute a priority
for conducting direct etiological studies. Additionally, interventions aimed to reduce potential PD undiagnosis might be
most appropriate in the South.
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Background
The purpose of this study was to detect spatially uneven
mortality from Parkinson's disease (PD) in Spain as a tool
potentially useful for design of focused etiological
research and interventions aimed to reduce possible PD
undiagnosis and undertreatment. The first aim requires a
detailed positioning with regard to causality in PD. The
second one, will consider comparisons with geographical
patterns of levodopa use (LDU).
The aetiology of the most common forms of Parkinson's
Disease (PD), whether sporadic or familial, is poorly
understood. Genetic heterogeneity, with at least eight sus-
ceptibility loci, has been implicated in rare, monogenic,
familial forms [1]. Nevertheless, low concordance in
twins [2], familial-aggregation patterns [3], birth-cohort
effects [4], and the results of diverse genome-wide linkage
and association studies [1,5,6], albeit debated, support
the contention that the large majority of sporadic PD cases
result from a synergistic effect of multigenic inheritance
and environmental factors. The nature of Lewy bodies, a
hallmark of late-onset PD neurodegeneration, consisting
of deposits of aggregated misfolded α-synuclein and other
proteins through the dysfunctioning of α-synuclein and
other genes, may, in part, have elucidated molecular phe-
nomena responsible for monogenic familial and some
sporadic PD forms [7,8]. Exposure to combined environ-
mental chemicals, such as pesticides and metals, may alter
α-synuclein and dopaminergic function in the substantia
nigra [9-12]. In addition, a mitochondrial complex I func-
tion defect --described in brain tissue and platelets of
patients affected by sporadic PD-- has been proposed as a
plausible pathophysiological apoptotic mechanism
shared by most PD forms [13-15]. Through activation of
apoptotic molecular pathways, mitochondrial poisons,
such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) and rotenone, lead to degeneration of substantia
nigra pars compacta, of a type similar to that seen in PD
[16,17]. Likewise, many other oxidative stress-inducing
agents lead to activation of mitochondrial apoptotic path-
ways [10]. Recently-published animal model studies are
consistent with a complex aetiology for late-onset PD, i.e.,
multigenic susceptibility paving the way for a neurodevel-
opmental basis plus environmental toxic multi-insults or
ageing [18]. However, evidence from PD natural history
or epidemiology which supports specific steps, is sparse.
Clinical and experimental MPTP observations in the early
1980s fuelled the search for environmental toxins poten-
tially implicated in PD; paraquat, a herbicide chemically
similar to MPTP, was perhaps the first of a series of such
hypotheses relating to various manmade toxins, with pes-
ticides being by far the most frequently investigated
[9,10,12,19]. A detailed review of five cohort studies, 38
separate case-control studies and one meta-analysis on
pesticide risk, supported by even more recent findings
[20], concluded that there does indeed appear to be evi-
dence of a potential role of pesticides in the development
of PD, with the current body of evidence being insuffi-
cient to establish causation for any specific pesticide [21].
Conversely, an ubiquitous natural toxin, Pertussis toxin,
mediated by high age at infection, or dietary exposure to
marine food contaminants has been proposed as aetiolog-
ical environmental factors explaining birth-cohort effects
in Iceland and high PD prevalence in geographical iso-
lates, i.e., in Iceland, Greenland and the Faroe Islands
[19,22,23].
Studies able to indicate geographical regions with a poten-
tially high incidence of PD can be crucial for planning
analytical surveys or case-control studies aimed at testing
specific hypotheses on industrial pollutants, such as pesti-
cides, insecticides and heavy metals claimed to be poten-
tially relevant for the disorder [24]. The publication of
European Pollutant Emission Register-Spain (EPER-
Spain) data enables the presence of geographical patterns
linked to industrial pollution to be investigated [25,26].
In Europe, Spain has been the leading polluter in almost
one third of all EPER pollutant substances released into
the environment, and ranks among the top three leading
polluters in two-thirds of all such substances. In addition
use of pesticides in agriculture has been historically
important in Spain. For a number of years, however, the
only nation-wide source of PD diagnostic and residential
data has been the cause-of-death registry. A recent disease-
mapping mortality study in Spain, in which PD was
included, disclosed an unexpected spatial pattern for this
disorder [27].
This paper thus sought to: describe and map the munici-
pal distribution of parkinsonism-related mortality in
Spain; discuss possible determinants of patterns; and indi-
cate the most promising study populations for the pur-
pose of undertaking direct studies (which tend to be
expensive) aimed at investigating the relationship
between industrial pollutant emissions and PD or to
reduce PD undiagnosis. This study did not quantitatively
analyse the relationship between industrial pollutants
and PD mortality.
Methods
Spanish municipal populations, broken down by age
group (18 groups) and sex, were obtained from the 1991
census and 1996 municipal roll. These years correspond
to the midpoints of the two quinquennia that comprise
the study period (1989-1993 and 1994-1998). The per-
son-years for each five-year period were obtained by mul-
tiplying these populations by 5.BMC Public Health 2009, 9:445 http://www.biomedcentral.com/1471-2458/9/445
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For our case source, we used individual death entries for
the period 1989-1998, corresponding to Parkinson's dis-
ease (International Classification of Diseases 9th Revision
(ICD-9) code 332.0) as the underlying cause of death,
broken down by town or city, nation-wide. These data
were furnished by the National Statistics Institute (Insti-
tuto Nacional de Estadística - INE) for the production of a
municipal cancer mortality atlas of which these results
form part [27].
Standardised mortality ratios (SMRs) were calculated as
the ratio of observed to expected deaths. For the calcula-
tion of expected cases, the overall Spanish mortality rates
for the above two 5-year periods were multiplied by each
town's person-years, by age group, sex and quinquen-
nium.
For map-plotting purposes, smoothed municipal relative
risks (RRs) were calculated, using the conditional autore-
gressive model proposed by Besag, York and Molliè
(BYM). This model was introduced by Clayton and Kaldor
[28], developed by BYM [29], and subsequently applied
in the field of ecological studies [30]. These models are
based on fitting Poisson spatial models with observed
cases as the dependent variable, expected cases as offset,
and two types of random effects terms which take the fol-
lowing into account: a) municipal contiguity (spatial
term); and b) municipal heterogeneity. The models were
fitted using Markov chain Monte Carlo simulation meth-
ods with non-informative priors [31]. Posterior distribu-
tions of relative risk were obtained using WinBugs [32].
The criterion of contiguity used was adjacency of munici-
pal boundaries. Convergence of the simulations was veri-
fied using the Bayesian Output Analysis (BOA) R
programme library [33]. Given the great number of
parameters of the models, the convergence analysis was
performed on a randomly selected sample of 10 towns
and cities, taking 4 strata defined by municipal size. Con-
vergence of the estimators was achieved before 100,000
iterations. For the maps shown, a "burn-in" (iterations
discarded to ensure convergence) of 300,000 iterations
was performed and the posterior distribution was derived
with 5,000.
A Geographic Information System was used to plot
municipal maps that depicted smoothed RR estimates and
the distribution of the posterior probability (pp) that
RR>1 (Bayesian version of p value). With regard to this
indicator, we followed Richardson's criterion [34], which
recommends that probabilities above 0.8 should be
deemed significant.
Results and Discussion
From 1989 to 1998, a total of 12531 PD deaths were reg-
istered in Spain, 6311 in men and 6220 in women. Sum-
mary statistics for population and PD deaths in 8077
municipalities are shown in Table 1. In 5266 towns and
cities no death due to this cause was registered. Using
these data it was possible to ascertain the posterior distri-
bution of relative risk on the basis of a single spatial
model that included all of Spain's 8077 towns and cities
and the 46398 adjacencies existing between them.
Figure 1 depicts the distribution of: a) the smoothed RRs
for PD (both sexes): and b) the posterior probability (pp)
that RR>1. This second map "filtered" the first, by flagging
the areas in which excess mortality was more likely. Since
sex-specific patterns were similar [27], the results for both
sexes were graphically depicted here.
While the most striking spatial high-mortality pattern cor-
responded to the north-eastern area of the Lower Ebro val-
ley in Catalonia, centred on Tarragona, the lowest
mortality was observed in the south-east, in an area cover-
ing part of the provinces of Jaén, Granada, Almería, Albac-
ete and Murcia, and in the south-west, in the provinces of
Seville and Cadiz. All three patterns would suggest a clus-
tering of several municipalities. Other large geographic
areas to register the highest mortality were located in
northern provinces, in regions such as Asturias and the
Basque Country, as well as in the Balearic Islands.
Figures for towns with RRs of over 1.3 after smoothing
and a posterior probability >0.80 of having an RR >1, are
shown in Table 2 grouped by province. Unlike Pozuelo de
Alarcon (Madrid), six out of seven towns with RRs >2,
such as Cambrils, Montblanc and Tarragona in the Lower
Table 1: Summaries of population and PD mortality in Spain's 8077 towns: 1989-1998.
Number Mean Median Standard deviation Minimum Maximum No. (%) of areas with zero counts
Population 39960592 4947.45 594 42459,34 5 2866850 0 (0)
Observed PD 12531 1.55 0 14.53 0 888 5266 (65.2)
Expected PD 13168 1.63 0.357 15.59 0 1078.41 2 (0)
PD SMRs - 0.83 0 2.10 0 43.48 5264 (65.2)BMC Public Health 2009, 9:445 http://www.biomedcentral.com/1471-2458/9/445
Page 4 of 14
(page number not for citation purposes)
Municipal distribution of Parkinsonism mortality in Spain: 1989--1998 Figure 1
Municipal distribution of Parkinsonism mortality in Spain: 1989--1998. Upper: Distribution pattern of smoothed rela-
tive risk (RR) under the BYM model. Lower. Posterior probability of RR being greater than 1. Spain 1989--1998.
Parkinson's Disease. 1989-1998
Posterior Probability RR>1
0.9 - 1   (140)
0.8 -   (232)
0.2 -   (5342)
0.1 -   (1699)
0 -   ( 7 7 9 )
Pk i D i
Parkinson's Disease.  1989-1998
Smoothed RR
>= 1.50   (147)
1.30 -   (278)
1.10 -   (739)
1.05 -   (307)
0.95 -   (1008)
0.91 -   (742)
0.77 -   (3285)
0.67 -   (1311)BMC Public Health 2009, 9:445 http://www.biomedcentral.com/1471-2458/9/445
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Table 2: Municipalities with 10 or more observed deaths due to Parkinson Disease, RRs >= 1.3 and a posterior probability >= 0.80 of 
having an RR greater than 1.
Province INE code Town/Municipality Observed number of 
deaths
Expected number of deaths SMR RR
Alava 1059 Vitoria-Gasteiz* 78 56.9 1.37 1.32
Asturias 33024 Gijón* 143 94.4 1.51 1.49
33035 Llanera* 11 4.4 2.51 1.68
33037 Mieres del Camino* 33 18.8 1.75 1.54
33044 Oviedo* 100 71.5 1.40 1.37
33051 Pravia 11 5.6 1.97 1.44
33060 San Martín del Rey Aurelio 19 7.9 2.41 1.82
33066 Siero 22 16.3 1.35 1.31
7033 Manacor 24 11.2 2.14 1.90
7054 Santa Eulalia del Río 10 4.8 2.10 2.04
Barcelona 8019 Barcelona* 888 678.8 1.31 1.30
8056 Castelldefels 23 7.8 2.94 2.26
8096 Granollers 25 13.9 1.80 1.51
8102 Igualada 24 12.6 1.91 1.65
8112 Manlleu 10 5.3 1.87 1.45
8125 Montcada I Reixac* 12 6.8 1.77 1.32
8187 Sabadell 84 57.9 1.45 1.40
8266 Cerdanyola del Vallès* 14 9.0 1.55 1.30
8298 Vic 17 11.3 1.51 1.35
8305 Vilafranca del Penedès* 16 9.9 1.63 1.47
8307 Vilanova I la Geltrú* 22 15.1 1.45 1.44
A Coruña (Corunna) 15001 Abegondo 10 3.2 3.12 1.36
15078 Santiago de Compostela 40 25.1 1.59 1.31BMC Public Health 2009, 9:445 http://www.biomedcentral.com/1471-2458/9/445
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Ebro valley and Felanixt, Eivissa and Santa Eulalia in the
Balearic Islands, appeared to come within "hot spots".,
Montblanc, however, was the only town displaying peak
RR values >2, which had at least one EPER industry at a
distance of less than 2 km from the municipal centroid.
Fifteen out of 40 towns with higher-than-expected values
in the table had a minimum of one EPER industry at a dis-
tance of less than 2 km from the municipal centroid.
Gerona 17015 Banyoles 11 5.5 2.01 1.61
17114 Olot 23 12.8 1.80 1.51
17117 Palafrugell 11 6.3 1.74 1.37
Guipuzkoa 20055 Arrasate O Mondragon 10 6.7 1.49 1.33
Huesca 22048 Barbastro* 12 6.6 1.82 1.37
Madrid 28080 Majadahonda 14 5.2 2.69 1.651
28115 Pozuelo de Alarcón 29 9.8 2.95 2.12
Murcia 30005 Alcantarilla 14 6.8 2.06 1.59
Tarragona 43038 Cambrils 14 4.1 3.41 2.21
43086 Montblanc* 12 2.5 4.77 2.46
43148 Tarragona* 48 32.1 1.50 1.48
43161 Valls 22 8.1 2.73 2.18
Valencia 46085 Carlet 15 5.7 2.64 1.51
46244 Torrent 33 14.0 2.35 1.73
Vizcaya 48036 Galdakao* 11 6.0 1.83 1.42
48044 Getxo* 31 22.4 1.38 1.33
Zaragoza 50067 Calatayud 19 9.0 2.12 1.48
* A minimum of one EPER industry at a distance of less than 2 km from municipal centroid.
Table 2: Municipalities with 10 or more observed deaths due to Parkinson Disease, RRs >= 1.3 and a posterior probability >= 0.80 of 
having an RR greater than 1. (Continued)BMC Public Health 2009, 9:445 http://www.biomedcentral.com/1471-2458/9/445
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Shown in Table 3 are the figures for municipalities with 5
or more expected deaths, RRs <1.0 after smoothing and a
posterior probability <= 0.10 of having an RR >1 (mortal-
ity deficit), regardless of the number of observed deaths.
Lowest values, RR <0.6, were seen for 12 towns with pop-
ulations ranging from 8891 in Ortigueira (Corunna) to
85884 in San Fernando (Cadiz). A considerable propor-
tion, 32/72, of such towns, had a minimum of one EPER
industry at a distance of less than 2 km from the munici-
pal centroid.
The above-mentioned 12 towns listed in Table 3, which
exhibited the lowest values, RR <= 0.6, and towns with
higher-than-expected RR values, whether or not included
in Table 2, which had at least one EPER industry at a dis-
tance of less than 2 km from the municipal centroid, are
pinpointed in the map in Figure 2. In general, low-mortal-
ity towns (shown in green) were grouped in the north-east
and south-west. A considerable number of towns with
high mortality and at least one EPER industry at a distance
of less than 2 km from the municipal centroid (shown in
red) were located in the above-mentioned "hot spots" in
the north, and in the north-east along the northern sector
of the Ebro basin. However, a few others, such as Jerez de
los Caballeros (Badajoz) in the south-west, Tenerife
(Canary Islands) and Alcalá de Henares (Madrid) corre-
sponded to distinct, isolated areas, seen against a low-
mortality background in Figure 1.
Discussion
To our knowledge, this study is the first ever attempt to
disclose differences in the spatial distribution of PD mor-
tality in populations resident in small areas nation-wide.
Results suggest that there is a considerable variation, with
a south-north gradient and some potential clusters. Differ-
ences should be associated with PD or PD-like disorders,
since PD is the most frequent type of parkinsonism. Nev-
ertheless, they could be explained by other multiple single
or combined factors, such as ascertainment, reporting, or
specific aetiological factors, including potential exposure
to environmental contaminants and persistent organic
pollutants in particular.
Mortality statistics on PD are difficult to interpret because
reporting bias may not only be frequent but may also
change with time and place. A review [24] pertinent to our
study period reported that: 1) in clinical series, the pro-
portion of PD sufferers whose death certificates made no
mention of the disease ranged from 68% in Iceland to
81% in Rochester; and 2) in those cases where PD was
reported, the annual proportion recorded as the underly-
ing cause of death in Sweden ranged from 46% to 81%,
and varied by county. The shift that took place in Sweden
in the early 1980s from recording PD as a contributory
cause of death to recording it as the underlying cause of
death, was attributed to late implementation of a World
Health Organisation (WHO) recommendation: even if
this had been present in Spain, where the underlying
cause of death was studied, it nevertheless occurred before
our study period and so could not affect these results.
Changes in death-certificate coding of PD during the
study period would generate an effect perceived at the
level of administrative regional boundaries, something
that is not seen in the maps. An internationally described
PD mortality pattern, observed for instance in the USA,
Sweden, the UK and Spain, corresponds to an ubiquitous
increase with advanced age and a decrease at lower ages
[24]. In Spain, age-period-cohort analysis revealed an
increase in both sexes as a period effect since 1970, and as
an inverted-U cohort effect with highest mortalities for
cohorts born around 1910 and lowest mortalities in
recently-born cohorts [35]. We propose that, since
mapped PD mortality would mainly reflect mortality
among the elderly, the geographical pattern might be
principally determined by specific changes across time-
spatially sensitive, i.e., non-simultaneous, improvement
in medical services in terms of diagnosing late-onset PD.
Since prevalent undiagnosed PD as seen from Spanish
population screening surveys ranged from 12% to 69%
[36], and PD incidence in a Spanish population aged 65
years and over [37] was ten times higher than PD mortal-
ity yielded by our study, PD diagnosis reported at death
probably had a low sensitivity for PD. Low death-record
sensitivity for PD might be due to low PD ascertainment
at death, low reporting bias or low mortality/fatality of PD
patients. Since all-cause mortality in the general popula-
tion is higher in the south [27], it would seem difficult to
explain the south-north pattern in terms of the effect of
high general mortality on PD patients.
To a certain extent, the PD mortality pattern described fits
that reported for LDU and provincial PD mortality
[38,39] (Figure 3). In 1992, Bruguera et al. [38] had
already noticed the similarity between PD mortality in the
1980-1985 period and the provincial LDU pattern in
1984 [39]. Cuadrado et al analysed age-adjusted LDU
from 1990 to 1995, and reported high drug sales in the
northern coastal areas and in Catalonia, and low drug
sales in the south and south-west of the country [40],
which fits the municipal pattern shown here rather well.
In brief, it would appear that the major features of spatial
distribution of municipal PD mortality in Spain corre-
spond to geographical differences seen for LDU, shared by
both sexes, and persisting across time. Since prescription
of levodopa, a relatively disease-specific therapy, and
reporting PD as a cause of death require PD diagnosis, it
would appear that PD aetiology, PD underascertainment
or both constitute potential explanations for the spatialBMC Public Health 2009, 9:445 http://www.biomedcentral.com/1471-2458/9/445
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Table 3: Towns with lower-than-expected PD mortality. Towns with 5 or more expected deaths from Parkinsonism and a posterior 
probability <= 0.10 of having an RR greater than 1
Province INE code Town/Municipality Observed number of deaths Expected number of deaths SMR RR
Albacete 2009 Almansa* 1 7.28 0.14 0.62
2081 Villarrobledo* 1 6.42 0.16 0.55
Alicante 3011 Alfaz del Pi 0 5.71 0 0.59
3031 Benidorm 1 10.71 0.09 0.52
3133 Torrevieja 3 10.46 0.29 0.59
Barcelona 8015 Badalona* 42 52.60 0.80 0.84
8101 Hospitalet de Llobregat (L') 58 71.91 0.81 0.82
8211 Sant Feliu de Llobregat* 1 8.35 0.12 0.69
Burgos 9219 Miranda de Ebro* 4 12.36 0.32 0.66
Cadiz 11006 Arcos de La Frontera* 2 5.76 0.35 0.64
11012 Cadiz 25 36.76 0.68 0.67
11015 Chiclana de La Frontera 4 7.64 0.52 0.66
11020 Jerez de La Frontera* 25 38.65 0.65 0.68
11031 San Fernando 6 16.48 0.36 0.53
11032 Sanlúcar de Barrameda 7 10.66 0.65 0.71
Castellón 12040 Castellón de La Plana/Castello* 26 41.37 0.63 0.69
CiudadReal 13039 Daimiel 3 6.05 0.49 0.74
13053 Manzanares 1 6.30 0.16 0.63
13082 Tomelloso 5 9.82 0.51 0.65
13087 Valdepeñas 6 8.79 0.68 0.71
14021 Cordoba* 61 80.90 0.75 0.76
Cordoba 14056 Puente Genil 5 7.93 0.63 0.74
Corunna
(A Coruña)
15005 Arteixo* 0 5.15 0 0.60
15019 Carballo 5 8.89 0.56 0.68
15036 Ferrol 23 31.18 0.72 0.73
15054 Narón* 6 9.43 0.64 0.69
15061 Ortigueira 1 6.10 0.16 0.59
18023 Baza 1 6.88 0.14 0.54BMC Public Health 2009, 9:445 http://www.biomedcentral.com/1471-2458/9/445
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Granada 18089 Guadix* 5 5.50 0.91 0.72
Huelva 21072 Valverde del Camino 1 5.26 0.19 0.63
Jaén 23002 Alcalá la Real 3 8.20 0.37 0.64
23005 Andujar* 7 10.16 0.69 0.76
23055 Linares* 13 15.56 0.84 0.75
23060 Martos 5 7.86 0.64 0.72
23087 Torredonjimeno* 3 5.04 0.59 0.73
23092 Ubeda 3 9.22 0.32 0.55
León 24089 León* 33 52.78 0.62 0.66
24115 Ponferrada* 15 19.34 0.77 0.77
Logroño 26036 Calahorra 2 7.32 0.27 0.75
Lugo 27028 Lugo 25 32.51 0.77 0.77
27057 Sarriá* 5 6.96 0.72 0.73
27066 Viveiro 4 6.58 0.61 0.70
Madrid 28007 Alcorcón 10 24.91 0.40 0.64
28065 Getafe 19 25.18 0.75 0.81
28079 Madrid* 732 1078.4 0.68 0.68
Malaga 29067 Malaga* 120 133.03 0.90 0.89
Murcia 30003 Aguilas 4 6.99 0.57 0.65
30015 Caravaca de La Cruz 2 8.28 0.24 0.55
30016 Cartagena* 34 45.53 0.75 0.76
30017 Cehegín 4 5.32 0.75 0.71
30022 Jumilla 3 6.72 0.44 0.70
30024 Lorca* 17 21.38 0.79 0.74
30039 Totana 3 6.81 0.44 0.66
Navarre 31201 Pamplona/Iruña 48 63.13 0.76 0.77
Ourense 32019 Carballino (O) 0 6.01 0 0.57
Las Palmas 35026 Telde* 8 13.47 0.59 0.75
Pontevedra 36042 Ponteareas 1 5.47 0.18 0.55
36052 Silleda 2 5.56 0.36 0.67
Table 3: Towns with lower-than-expected PD mortality. Towns with 5 or more expected deaths from Parkinsonism and a posterior 
probability <= 0.10 of having an RR greater than 1 (Continued)BMC Public Health 2009, 9:445 http://www.biomedcentral.com/1471-2458/9/445
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36055 Tui 2 5.59 0.36 0.58
36057 Vigo* 60 76.29 0.78 0.77
Santander 39075 Santander* 57 69.22 0.82 0.83
Seville 41004 Alcalá de Guadaira* 9 11.28 0.80 0.75
41024 Carmona* 2 6.99 0.28 0.62
41038 Dos Hermanas* 10 15.64 0.64 0.72
41053 Lebrija 3 5.52 0.54 0.69
41060 Marchena* 2 5.31 0.37 0.67
41065 Morón de La Frontera* 3 8.06 0.37 0.63
41091 Seville* 147 184.31 0.80 0.80
Teruel 44216 Teruel* 10 11.96 0.84 0.78
Valencia 46022 Alfafar 1 5.03 0.20 0.71
46105 Cullera 3 7.40 0.41 0.72
46131 Gandía 8 14.66 0.55 0.72
* A minimum of one EPER industry at a distance of less than 2 km from municipal centroid.
Table 3: Towns with lower-than-expected PD mortality. Towns with 5 or more expected deaths from Parkinsonism and a posterior 
probability <= 0.10 of having an RR greater than 1 (Continued)
Geographical location of selected data Figure 2
Geographical location of selected data, i.e., municipalities with higher-than-expected RR values, whether or not included 
in Table 2, with a minimum of one EPER industry at a distance of less than 2 km from municipal centroid (red), and 12 munici-
palities listed in Table 3 registering lowest, RR <= 0.6 values (green).BMC Public Health 2009, 9:445 http://www.biomedcentral.com/1471-2458/9/445
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patterns observed by us, thereby rendering resort to
potential PD reporting bias in death records unnecessary.
Despite the fact that a higher incidence of PD among men
has been documented in a Spanish population [37], the
similar geographical mortality pattern among men and
women (not shown here) would point to causes of geo-
graphical variation determined by incidence unconnected
with occupation. It would be difficult for differential mis-
diagnosis of PD, such as overdiagnosis (i.e., low specifi-
city), to underlie spatial variation, since PD-like forms of
parkinsonism are excluded as a potential explanation due
to their considerably lower prevalence [Spanish Group for
Epidemiological Study of the Aged, unreported].
Door-to-door PD prevalence surveys have been conducted
on four Spanish populations [41-45]. All of these dis-
played medium prevalence, except the town of Cantalejo
in the Province of Segovia, where the high prevalence
detected among the elderly segment aged over 80 years
was attributed to detailed and intensive case-finding [45].
None of these populations was located in any of the mor-
tality "hot spots" identified by us. Neither unreported PD
surveys conducted in the Hondarribia district in the
Basque Country [46], Arosa Island. [47] and selected sub-
populations in Central Spain with medium prevalences
[Spanish Groups for Epidemiological Study of the Aged,
unreported], nor a survey based on diagnoses collected by
the medical services in Lower Aragon, a region lying close
to the north-eastern cluster [48], are of any help when it
comes to interpreting our mortality findings for specific
towns.
While EPER industries were located in the vicinity of
many towns with high or low PD mortality, the excess
mortality registered in many towns in Catalonia, the
Basque Country, Huesca, Asturias and Tarragona is con-
sistent with the traditional, well-documented industrial
toxic emissions reported in these places [26,27]. The mor-
tality cluster in the Province of Tarragona warrants special
attention, since the province encompasses the eastern-
most stretch of the Ebro basin which historically accumu-
lated the industrial pollution borne by the Ebro River,
potentially acting via water and, essentially, through the
food chain and diet. Tens of thousands of tons of waste,
consisting mainly of several hexachlorocyclohexane
(HCH) isomers, were dumped near factories in the
Basque Country and the Province of Huesca, namely, in
Barakaldo from 1947-1987, in Erandio from 1952-1982
and in Sabiñanigo, with the HCH isomers being dissemi-
nated by lixiviation and environmental conditions, and
being detected in tributaries of the Ebro River [49]. For
over a century, an electrochemical plant and a chemical
factory located at Flix have polluted the river and the
region with organochlorine compounds and mercury.
This pollution has been detected in the ecosystems of the
Ebro River delta area [50,51] and in human serum
[52,53], with high levels of hexachlorobenzene and other
organochlorine compounds being found during preg-
nancy and in cord blood [54-56]. Despite the fact that the
chemical factories and waste areas are situated close to or
not very far from the PD "hot spots" described here, our
findings align better with historical exposures of the type
reported in the EPER involving emissions from multiple
industrial plants near the city of Tarragona, in which lead,
cadmium and other organic and inorganic industrial
chemicals are included [57].
However, some results for PD mortality clusters also devi-
ate from biologically expected patterns. Firstly, low PD
mortality is seen in environmentally polluted areas, such
as in Huelva, or in the Gibraltar area in southern Spain
where both cancer mortality and registered industrial pol-
lution are high [26-28,58]. Secondly, the lack of excess
cancer mortality seen in towns in the Province of Tarrag-
ona is difficult to reconcile with high, historically long-
lasting industrial pollution and high PD mortality. Third,
the lower mortality in Benidorm and the Canary Islands
contrasts with the high mortality in the Balearic Islands
where the possible weight of the foreign, aged, European
resident population should be considered.
Attempts have occasionally been made to link parkinson-
ism to industrial pollutants but hypotheses (those target-
ing heavy metals being frequently mentioned) lack
confirmation, generally as well as specifically, in the form
of recent gene-environment interaction analysis [59].
Manganese, carbon disulphide, carbon monoxide after
acute poisoning, cyanide, n-hexane and other chemical
toxicity may include features mimicking parkinsonism
[60-62]. Exposure to β-HCH has recently been reported as
a risk factor for PD [12]. Were one to speculate, PD mor-
tality clusters in northern Spain and Catalonia might be
consistent with Gorell et al's hypothesis, suggesting that
there is a large array of compounds that may alter the
nigrostriatal dopaminergic pathway and induce neural
oxidative stress, leading to the development of PD [10] in
which the reported effects of ubiquitous organohalogen
xenobiotics --mainly organochlorines-- and polychlorin-
ated biphenyls (PCBs) might be implicated [11,63-66]. In
contrast, a few of the above-mentioned towns with high
mortality deserve particular attention because they were
located in areas of low industrial activity and low PD mor-
tality, displaying a history of isolated and selective envi-
ronmental industrial pollution at a distance of less than 2
km from their municipal centroids, such as Jerez de los
Caballeros (Badajoz) in the south-east and Alcalá de Hen-
ares (Madrid) in central Spain [25,26]. While familial par-
kinsonism similar to that found in a small community in
the Province of Soria [67] might account for isolated spotsBMC Public Health 2009, 9:445 http://www.biomedcentral.com/1471-2458/9/445
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of high PD mortality, the towns with high mortality listed
in Table 2 have larger populations. However, there are
other reasons for caution, particularly when interpreting
such high mortality values in industrial areas. Because
EPER facilities are registered insofar as the emissions lev-
els exceed certain threshold levels, absence of EPER facili-
ties in the database does not necessarily mean that
industrial emissions are low. In several countries or
regions within the EU, there might be a concentration of
small to medium size industries, none attaining the
threshold for any single pollutant, and where cumulative
total emissions are high. Hence caution should be given
not to equate absence of EPER facility in a given city and
"low industrial activity". In summary, high mortality and
absence of EPER registered facility does not exclude a con-
cealed local positive association. To add, SMR values are
affected by population size in the town targeted.
Undiagnosed PD present until death, determining PD
underreporting at death certificate and low PD mortality,
should be suspected as a health-relevant explanation of
the lowest PD mortality observed in two broad areas, one
covering tracts of several provinces in the south-east, such
as Granada, Jaén and Almería, and another in the south-
west corresponding to Seville and Cadiz. Such areas dis-
played some of the lowest LDU rates from 1990 to 1995
[40], a period encompassed by our own study period, and
[39] the low PD mortality might also indicate historically-
persistent low access to PD diagnosis and treatment in
such regions, perhaps determined by lack of neurologists
at district hospital clinics in Andalucia. Several large
towns situated in the above-mentioned and other north-
eastern provinces pinpointed in Figure 3 or in neighbour-
ing areas, might be proposed for primary care interven-
tion using reported procedures designed to uncover the
potential limitations of medical services in diagnosing
and treating PD [68,69].
Internal migration during the 1960s and 1970s to Madrid,
Catalonia/Barcelona and the Basque Country from poor
rural areas mainly located South and West [70], fitting
well with regions with low LDU and PD mortality, would
have induced patterns opposite to those observed. Neu-
roepidemiological PD research in such areas is still sparse.
Conclusion
This study provides a summarised report of spatial pat-
terns of municipal PD mortality roughly fitting those of
reported provincial mortality and levodopa use, with
municipal "hot spots", whether or not clustered, indicat-
Spatial patterns of reported provincial PD mortality (a) and use of levodopa (b, c, and d) in Spain Figure 3
Spatial patterns of reported provincial PD mortality (a) and use of levodopa (b, c, and d) in Spain.
LDU 1984. Crude Rate Ratio 
0.14 - 0.22
0.23 - 0.41
0.42 - 0.56
d
LDU 1990-1995. Age-adjusted Rate Ratio
0.44 - 0.64
0.65 - 0.92
0.93 - 1.09
b
LDU 1990-1995. Crude Rate Ratio
0.26 - 0.52
0.53 - 0.93
0.94 - 1.24
c
>3.21
2.14 – 3.20
< 2.13
Crude provincial mortality per 105 1980-1985
aBMC Public Health 2009, 9:445 http://www.biomedcentral.com/1471-2458/9/445
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ing populations of possible interest for direct studies, pur-
pose-designed to test specific PD aetiological hypotheses
or improving access to PD diagnosis and treatment.
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